Oncology Articles | Page 3

Global HPV Vaccination Reshaping Standard of Care for Cervical Cancer Prevention
Xavier Bosch, MD, discusses a second-generation vaccination against HPV for the prevention of cervical cancer.
Progress for TNBC Seen Across Treatment Modalities
Although chemotherapy remains the mainstay of treatment for patients with triple-negative breast cancer, promising developments are unfolding on several fronts, including new ways of using existing therapies and the exploration of immunotherapy, novel antibodies, and agents targeting the PI3K/mTOR/AKT pathway.
Neoadjuvant chemoradiotherapy did not lower postoperative health-related quality of life compared with surgery alone for patients with esophageal or junctional cancer.
FDA Expands Afatinib's Approval for Lung Cancer
The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.
Missing in Action: Patient Perspective on Cancer Trial Goal
There is a critically important subject associated with the clinical trial experience that has had inadequate discussion within the medical literature, regarding the role of the patient beyond agreeing to serve as a research subject. 
The effort to improve outcomes of disadvantaged patients involves every aspect of lung cancer care.
The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.
Experts Discuss Optimal Timing of New Prostate Cancer Therapies
Layering of therapies and advances in next-generation imaging and sequencing are key reasons that outcomes are improving in advanced prostate cancer.
Given that few options are available for intrahepatic cholangiocarcinoma, investigators are excited about a phase III trial of the multikinase inhibitor derazantinib as a second-line treatment for patients with inoperable or advanced disease.
The FDA approved the PARP inhibitor olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer. 
Publication Bottom Border
Border Publication